[go: up one dir, main page]

PH12020551547A1 - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation

Info

Publication number
PH12020551547A1
PH12020551547A1 PH12020551547A PH12020551547A PH12020551547A1 PH 12020551547 A1 PH12020551547 A1 PH 12020551547A1 PH 12020551547 A PH12020551547 A PH 12020551547A PH 12020551547 A PH12020551547 A PH 12020551547A PH 12020551547 A1 PH12020551547 A1 PH 12020551547A1
Authority
PH
Philippines
Prior art keywords
pharmaceutical preparation
provides
present
preparation
rosuvastatin
Prior art date
Application number
PH12020551547A
Inventor
Sang Yeop Kim
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of PH12020551547A1 publication Critical patent/PH12020551547A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a preparation containing fimasartan, amlodipine and rosuvastatin as active ingredients. The present invention provides a preparation having an excellent dissolution rate for each active ingredient and a high stability, thereby enabling the convenience of administration to be remarkably improved.
PH12020551547A 2018-04-30 2020-09-24 Pharmaceutical preparation PH12020551547A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180050277A KR101992400B1 (en) 2018-04-30 2018-04-30 Pharmaceutical formulation
PCT/KR2019/005151 WO2019212214A1 (en) 2018-04-30 2019-04-29 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
PH12020551547A1 true PH12020551547A1 (en) 2021-06-07

Family

ID=67055715

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551547A PH12020551547A1 (en) 2018-04-30 2020-09-24 Pharmaceutical preparation

Country Status (9)

Country Link
KR (1) KR101992400B1 (en)
CN (1) CN112040933A (en)
MX (1) MX2020010259A (en)
PH (1) PH12020551547A1 (en)
RU (1) RU2756452C1 (en)
SG (1) SG11202009187YA (en)
TW (1) TWI697339B (en)
WO (1) WO2019212214A1 (en)
ZA (1) ZA202006346B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102595702B1 (en) * 2021-06-09 2023-10-30 주식회사 보령 Pharmaceutical composite formulation and method of preparing pharmaceutical composite formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336922A (en) * 2008-08-08 2009-01-07 青岛黄海制药有限责任公司 Rosuvastatin amlodipine composition
HRP20181347T1 (en) * 2009-11-13 2018-10-19 Astrazeneca Ab TWO-TABLET FORMULATIONS
KR101058284B1 (en) 2010-01-22 2011-08-22 보령제약 주식회사 Novel Process for the Preparation of 2- (2-N-butyl-4-hydroxy-6-methyl-pyrimidin-5-yl) -N, N-dimethylacetamide
KR101168136B1 (en) * 2011-08-08 2012-07-24 보령제약 주식회사 Antihypertensive pharmaceutical composition
CA2866377C (en) * 2012-03-30 2020-02-11 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
CN103156842B (en) * 2013-03-08 2014-05-28 南开大学 Novel application of Arctigenin in preparation of anti-arrhythmia medicine
SG11201507305SA (en) * 2013-03-14 2015-10-29 Boryung Pharm Pharmaceutical combination drug
KR101910901B1 (en) * 2013-11-29 2018-10-24 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
PL3320903T3 (en) * 2015-07-08 2021-12-06 Hk Inno.N Corporation Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin
WO2017091041A1 (en) * 2015-11-26 2017-06-01 보령제약 주식회사 Novel salt of fimasartan

Also Published As

Publication number Publication date
KR101992400B1 (en) 2019-06-24
RU2756452C1 (en) 2021-09-30
WO2019212214A1 (en) 2019-11-07
SG11202009187YA (en) 2020-10-29
TW201946916A (en) 2019-12-16
ZA202006346B (en) 2022-01-26
CN112040933A (en) 2020-12-04
TWI697339B (en) 2020-07-01
MX2020010259A (en) 2020-10-22

Similar Documents

Publication Publication Date Title
PH12020550341A1 (en) Niraparib formulations
EA201792592A1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING TENOFOVIR AND EMTRICITABIN
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EA201792591A1 (en) PHARMACEUTICAL PREPARATIONS
MX2020005287A (en) Novel bradykinin b2 receptor antagonists.
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
MX2018000546A (en) Pharmaceutical composition containing celecoxib and tramadol.
MX380070B (en) Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
PH12020551547A1 (en) Pharmaceutical preparation
MX2018010065A (en) Oral dosage form comprising rifaximin in form beta.
EA201991286A1 (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
MX2017013643A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix.
MX394413B (en) Pharmaceutical composition containing clomipramine and preparation method therefor
MX2017013634A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a powder.
ZA202003904B (en) Drug delivery system
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
MX2017014725A (en) Dropropizine in combination with ambroxol in the dosage form of syrup or tablets.
MD20170094A2 (en) Process for manufacturing dry powder blends
PH12019501049A1 (en) Pharmaceutical composition containing palonosetron as active ingredient
PH12019500779A1 (en) Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin